SENGAI, Japan — RevolKa Ltd., a venture-backed biotech company specializing in AI-driven protein engineering, has announced the launch of a new contract research service called RevoAb™. This innovative service leverages RevolKa’s proprietary aiProtein® platform to enhance the developability of therapeutic antibodies by optimizing their physicochemical properties without compromising antigen binding affinity. Since December 2023, RevolKa has been providing contract research services for antibody engineering using its advanced AI technology. RevoAb™ builds on this foundation by offering a targeted solution to address key challenges in antibody drug development, such as poor solubility, aggregation, stability, and immunogenicity—issues that can hinder clinical success and manufacturing scalability. By applying machine learning models trained on vast datasets of protein sequences and structures, RevoAb™ identifies optimal amino acid modifications that improve stability, solubility, and overall biophysical performance. The platform ensures that these enhancements are achieved while preserving or even improving the antibody’s ability to bind its target antigen with high specificity and affinity. RevoAb™ is designed to accelerate the preclinical development phase for biopharmaceutical companies, reducing the time and cost associated with iterative experimental optimization. The service is particularly valuable for next-generation antibody therapeutics, including bispecifics, antibody-drug conjugates (ADCs), and engineered variants with enhanced pharmacokinetic profiles. RevolKa continues to expand its AI-powered capabilities, enabling faster, more predictable, and more efficient protein engineering solutions. The company’s mission is to transform the drug discovery and development process by harnessing the power of artificial intelligence to solve complex biological challenges.